hydroxychloroquine rheum
Selected indexed studies
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. (Ann Rheum Dis, 2024) [PMID:37827694]
- Update οn the diagnosis and management of systemic lupus erythematosus. (Ann Rheum Dis, 2021) [PMID:33051219]
- EULAR recommendations for the management of antiphospholipid syndrome in adults. (Ann Rheum Dis, 2019) [PMID:31092409]
_Worker-drafted node — pending editorial review._
Connections
hydroxychloroquine rheum is a side effect of
Sources
- Mechanism of action of hydroxychloroquine as an antirheumatic drug. (1993) pubmed
- EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. (2020) pubmed
- Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. (2023) pubmed
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. (2024) pubmed
- Update οn the diagnosis and management of systemic lupus erythematosus. (2021) pubmed
- 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. (2019) pubmed
- 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. (2020) pubmed
- EULAR recommendations for the management of antiphospholipid syndrome in adults. (2019) pubmed
- New Treatment Guidelines for Sjögren's Disease. (2016) pubmed
- EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. (2017) pubmed